Grifols, S.a. share price today

(GRFS)

Grifols, S.a. share price is $7.51 & ₹638.17 as on 21 Dec 2024, 2.30 'hrs' IST

$7.51

▲

-0.21

(-2.72%)

Market is closed - opens 8 PM, 23 Dec 2024

View live Grifols, S.a. share price in Dollar and Rupees. Guide to invest in Grifols, S.a. from India. Also see the sentimental analysis on Indian investors investing in Grifols, S.a.. Get details on the Indian mutual funds that are investing in Grifols, S.a.. Get Analyst recommendations and forecasts along with all the Grifols, S.a.'s financials.

Grifols, S.a. share price movements

Today's Low: $7.47
Today's High: $7.65
$7.51
0.6%
Downside
Day's Volatility :2.42%
Upside
1.83%
52 Weeks Low: $5.30
52 Weeks High: $12.15
$7.51
29.43%
Downside
52 Weeks Volatility :56.38%
Upside
38.19%

Grifols, S.a. Returns

Period	Grifols, S.a.	Sector (Health Care)	Index (Russel 2000)
3 Months	-14.66%	-10.6%	0.0%
6 Months	4.45%	-6.0%	0.0%
1 Year	-27.3%	2.2%	0.0%
3 Years	-34.24%	-0.9%	-21.1%

Grifols, S.a. Key Statistics

in dollars & INR

Previous Close	$7.72
Open	$7.65
Today's High	$7.65
Today's Low	$7.465
Market Capitalization	$7.1B
Today's Volume	$1.7M
52 Week High	$12.1499
52 Week Low	$5.3001
Revenue TTM	$7.0B
EBITDA	$1.3B
Earnings Per Share (EPS)	$0.26
PE Ratio	35.0
Profit Margin	2.31%
Quarterly Earnings Growth YOY	-0.67%
Return On Equity TTM	2.71%

How to invest in Grifols, S.a. from India?

It is very easy for Indian residents to invest directly in Grifols, S.a. from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Grifols, S.a. stock in both Indian Rupees (INR) and US Dollars (USD). Search for Grifols, S.a. or GRFS on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Grifols, S.a. or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Grifols, S.a. shares which would translate to 0.113 fractional shares of Grifols, S.a. as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Grifols, S.a., in just a few clicks!

Returns in Grifols, S.a. for Indian investors in Rupees

Investment Value

₹1,00,000

Grifols, S.a. investment value today

Current value as on today

₹74,897

Returns

₹25,103

(-25.1%)

Returns from Grifols, S.a. Stock

₹27,299 (-27.3%)

Dollar Returns

₹2,196 (+2.2%)

Indian investors sentiment towards Grifols, S.a.

-37%

Period: Sep 23, 2024 to Dec 22, 2024. Change in 30 Days versus previous period

Search volume for Grifols, S.a. on INDmoney from India has reduced in the last 30 days as on Dec 23, 2024. -37% less investors are searching Grifols, S.a. in the last 30 days versus the previous period.

Global Institutional Holdings in Grifols, S.a.

Capital World Investors
3.09%
Brandes Investment Partners & Co
2.93%
Permian Investment Partners
1.81%
Black Creek Investment Management Inc
1.63%
Millennium Management LLC
1.58%
Armistice Capital, LLC
1.40%

Analyst Recommendation on Grifols, S.a.

Buy

63%Buy

22%Hold

13%Sell

Based on 22 Wall street analysts offering stock ratings for Grifols, S.a.(by analysts ranked 0 to 5 stars)

Based on 22 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Grifols, S.a.

What analysts predicted

Upside of 42.08%

Current:

$7.51

Target:

$10.67

Insights on Grifols, S.a.

Price Movement
In the last 1 month, GRFS stock has moved down by -13.7%
Decreasing Revenue
Revenue is down for the last 2 quarters, 1.81B → 1.79B (in $), with an average decrease of 1.4% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, 14.84M → 51.69M (in $), with an average increase of 71.3% per quarter
GRFS vs LLY (1 yr)
In the last 1 year, Eli Lilly And Company has given 34.6% return, outperforming this stock by 62.2%
GRFS vs LLY (3 yr)
In the last 3 years, Eli Lilly And Company has given 181.1% return, outperforming this stock by 214.0%
Price to Sales
ForGRFS every $1 of sales, investors are willing to pay $1.5, whereas for Eli Lilly And Company, the investors are paying $16.9 for every $1 of sales.

Grifols, S.a. Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$4.5B	↑ 3.91%
Net Income	$596.6M	↓ 9.97%
Net Profit Margin	13.3%	↓ 2.05%

	FY19	Y/Y Change
Revenue	$5.1B	↑ 13.64%
Net Income	$625.1M	↑ 4.78%
Net Profit Margin	12.26%	↓ 1.04%

	FY20	Y/Y Change
Revenue	$5.3B	↑ 4.73%
Net Income	$618.5M	↓ 1.06%
Net Profit Margin	11.58%	↓ 0.68%

	FY21	Y/Y Change
Revenue	$5.6B	↓ 7.62%
Net Income	$299.9M	↓ 57.1%
Net Profit Margin	5.38%	↓ 6.2%

	FY22	Y/Y Change
Revenue	$6.4B	↑ 22.92%
Net Income	$220.4M	↓ 21.5%
Net Profit Margin	3.43%	↓ 1.95%

	FY23	Y/Y Change
Revenue	$7.2B	↑ 8.71%
Net Income	$64.7M	↓ 71.52%
Net Profit Margin	0.9%	↓ 2.53%

	Q2 FY23	Q/Q Change
Revenue	$1.8B	↓ 2.88%
Net Income	$65.1M	↑ 199.13%
Net Profit Margin	3.61%	↑ 2.44%

	Q3 FY23	Q/Q Change
Revenue	$1.7B	↓ 3.97%
Net Income	$63.6M	↓ 0.82%
Net Profit Margin	3.73%	↑ 0.12%

	Q4 FY23	Q/Q Change
Revenue	$1.9B	↑ 10.77%
Net Income	$61.1M	↓ 5.96%
Net Profit Margin	3.16%	↓ 0.57%

	Q1 FY24	Q/Q Change
Revenue	$1.6B	↓ 8.13%
Net Income	$21.4M	↓ 61.75%
Net Profit Margin	1.32%	↓ 1.84%

	Q2 FY24	Q/Q Change
Revenue	$2.0B	↑ 11.82%
Net Income	$16.0M	↓ 30.71%
Net Profit Margin	0.82%	↓ 0.5%

	Q3 FY24	Q/Q Change
Revenue	$1.8B	↓ 1.37%
Net Income	$51.7M	↑ 248.3%
Net Profit Margin	2.88%	↑ 2.06%

	FY18	Y/Y Change
Profit	$2.0B	↓ 4.76%

	FY19	Y/Y Change
Profit	$2.3B	↑ 14.23%

	FY20	Y/Y Change
Profit	$2.3B	↓ 3.68%

	FY21	Y/Y Change
Profit	$2.2B	↓ 12.97%

	FY22	Y/Y Change
Profit	$2.4B	↑ 13.7%

	FY23	Y/Y Change
Profit	$2.5B	↑ 4.09%

	Q2 FY23	Q/Q Change
Profit	$672.6M	↑ 3.5%

	Q3 FY23	Q/Q Change
Profit	$674.5M	↑ 1.9%

	Q4 FY23	Q/Q Change
Profit	$752.5M	↑ 9.18%

	Q1 FY24	Q/Q Change
Profit	$648.4M	↓ 6.0%

	Q2 FY24	Q/Q Change
Profit	$668.0M	↓ 4.26%

	Q3 FY24	Q/Q Change
Profit	$726.8M	↑ 17.07%

	FY18	Y/Y Change
Operating Cash Flow	$737.4M	↓ 12.39%
Investing Cash Flow	$-781.9M	↓ 64.23%
Financing Cash Flow	$152.5M	↓ 89.37%

	FY19	Y/Y Change
Operating Cash Flow	$568.9M	↓ 22.85%
Investing Cash Flow	$-548.8M	↓ 29.81%
Financing Cash Flow	$-332.4M	↓ 317.93%

	FY20	Y/Y Change
Operating Cash Flow	$1.1B	↑ 95.16%
Investing Cash Flow	$-858.1M	↑ 56.37%
Financing Cash Flow	$-354.4M	↑ 6.63%

	FY21	Y/Y Change
Operating Cash Flow	$674.9M	↓ 46.23%
Investing Cash Flow	$-33.2M	↓ 96.57%
Financing Cash Flow	$1.7B	↓ 515.61%

	FY22	Y/Y Change
Operating Cash Flow	$-11.5M	↓ 101.82%
Investing Cash Flow	$-2.1B	↑ 6632.29%
Financing Cash Flow	$-183.6M	↓ 111.78%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-45.9M	↓ 162.65%
Investing Cash Flow	$-133.3M	↑ 0.0%
Financing Cash Flow	$206.0M	↓ 6.07%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$166.1M	↓ 468.16%
Investing Cash Flow	$-131.2M	↑ 0.0%
Financing Cash Flow	$-84.7M	↓ 141.79%

Grifols, S.a. Technicals Summary

Sell

Neutral

Buy

Grifols, S.a. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Grifols, S.a. Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Grifols, S.a.	-12.67%	4.45%	-27.3%	-34.24%	-67.86%
Eli Lilly And Company	1.69%	-13.75%	34.54%	175.77%	485.45%
Johnson & Johnson	-7.26%	-3.12%	-7.47%	-14.85%	-0.93%
Merck & Co. Inc.	-3.07%	-26.26%	-8.9%	28.05%	7.35%
Novo Nordisk A/s	-18.71%	-40.26%	-17.22%	52.29%	192.65%
Abbvie Inc	-0.84%	1.64%	13.56%	30.63%	95.46%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Grifols, S.a.	35.0	35.0	0.23	0.68	0.03	0.03	NA	7.87
Eli Lilly And Company	81.9	81.9	0.71	13.15	0.65	0.14	0.01	15.83
Johnson & Johnson	23.73	23.73	0.86	9.96	0.21	0.08	0.03	29.14
Merck & Co. Inc.	20.82	20.82	0.07	7.74	0.28	0.11	0.03	17.58
Novo Nordisk A/s	34.71	34.71	1.54	22.85	0.89	0.21	0.01	27.07
Abbvie Inc	59.97	59.97	0.41	10.94	0.56	0.08	0.04	3.41

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Grifols, S.a.	Buy	$7.1B	-67.86%	35.0	2.31%
Eli Lilly And Company	Buy	$681.3B	485.45%	81.9	20.48%
Johnson & Johnson	Buy	$345.7B	-0.93%	23.73	16.74%
Merck & Co. Inc.	Buy	$251.7B	7.35%	20.82	19.23%
Novo Nordisk A/s	Buy	$482.1B	192.65%	34.71	35.01%
Abbvie Inc	Buy	$303.1B	95.46%	59.97	9.22%

Grifols, S.a. Dividend announcements

Grifols, S.a. Dividends June, 2021
In the quarter ending June,2021. Grifols, S.a. has declared dividend of $0.46
Read More

About Grifols, S.a.

for more than 75 years, grifols has been improving the health and well-being of people. our patients are our priority, and our commitment to their health has enabled us to become a global healthcare leader with presence in more than 100 countries. the grifols legacy embodies a spirit of innovation and a forward thinking approach and establish us as an international benchmark in the plasma collection market, the production of plasma derived therapies and transfusion medicine. grifols has three business divisions: bioscience brings together all plasma related activities including research, development, collection, production and sales of life-saving plasma derived therapies. diagnostic provides innovative solutions to support safe and compatible transfusions, monitor therapies, and detect infectious and autoimmune diseases. research novel technologies to further improve treatment outcomes and laboratory efficiency. hospital specializes in non-biological pharmaceutical products. t

Organization	Grifols, S.a.
Employees	23000
CEO	Mr. Jose Ignacio Abia Buenache
Industry	Health Technology

Management People of Grifols, S.a.

Name	Title
Mr. Jose Ignacio Abia Buenache	CEO & Director
Mr. Alfredo Arroyo Guerra CPA	CFO & VP
Mr. Lluis Pons Gomez	Senior Vice President of Strategy & COO Office
Ms. Nuria Pascual Lapeña	VP of Corporate Treasury, Risk Management Investor Relation & Sustainability Officer
Mr. David Ian Bell	Chief Corporate Development, Legal & Data Protection Officer
Ms. Maria Teresa-Rioné Llano	Chief Communications Officer
Mr. Camille Alpi	Chief Human Resources & Talent Officer
Mr. Vicente Blanquer Torre	Chief Quality Officer
Mr. Sergio Roura Adell	President of Commercial Tech Support
Mr. Víctor Grifols Deu	Executive Director

Important FAQs about investing in Grifols, S.a. from India :

What is Grifols, S.a. share price today?

Grifols, S.a. share price today stands at $7.51, Open: $7.65 ; Previous Close: $7.72 ; High: $7.65 ; Low: $7.47 ; 52 Week High: $12.15 ; 52 Week Low: $5.30. The stock opens at $7.65, after a previous close of $7.72. The stock reached a daily high of $7.65 and a low of $7.47, with a 52-week high of $12.15 and a 52-week low of $5.30.

Can Indians buy Grifols, S.a. shares?

Yes, Indians can invest in the Grifols, S.a. (GRFS) from India.

With INDmoney, you can buy Grifols, S.a. at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Grifols, S.a. at zero transaction cost.

How can I buy Grifols, S.a. shares from India?

It is very easy to buy Grifols, S.a. from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Grifols, S.a. be purchased?

Yes, you can buy fractional shares of Grifols, S.a. with INDmoney app.

What are the documents required to start investing in Grifols, S.a. stocks?

To start investing in Grifols, S.a., You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.